Inhibrx Biosciences, Inc. (INBX) stock
INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$69.06−5.12 (-6.90%)
Close on Nov 18, 2026Market cap $1.02BP/E –Yield –
Inhibrx Biosciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Inhibrx Biosciences's operating income for the twelve months ending Sep 30, 2026 was -$125.73M. For fiscal 2025 it was -$135.03M. The highest annual figure on record is -$43.71M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$135.03M | – |
| FY2024 | Dec 31, 2024 | -$331.45M | – |
| FY2023 | Dec 31, 2023 | -$219.22M | – |
| FY2022 | Dec 31, 2022 | -$129.12M | – |
| FY2021 | Dec 31, 2021 | -$76.56M | – |
| FY2020 | Dec 31, 2020 | -$67.44M | – |
| FY2019 | Dec 31, 2019 | -$43.71M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$31.74M | – |
| Q2 FY2026 | Jun 30, 2026 | -$32.15M | – |
| Q1 FY2026 | Mar 31, 2026 | -$30.93M | – |
| Q4 FY2025 | Dec 31, 2025 | -$30.92M | – |
| Q3 FY2025 | Sep 30, 2025 | -$33.81M | – |
| Q2 FY2025 | Jun 30, 2025 | -$27.39M | – |
| Q1 FY2025 | Mar 31, 2025 | -$42.90M | – |
| Q4 FY2024 | Dec 31, 2024 | -$49.93M | – |
| Q3 FY2024 | Sep 30, 2024 | -$46.80M | – |
| Q2 FY2024 | Jun 30, 2024 | -$160.90M | – |
| Q1 FY2024 | Mar 31, 2024 | -$73.83M | – |
| Q4 FY2023 | Dec 31, 2023 | -$88.29M | – |
| Q3 FY2023 | Sep 30, 2023 | -$45.83M | – |
| Q2 FY2023 | Jun 30, 2023 | -$41.34M | – |
| Q1 FY2023 | Mar 31, 2023 | -$43.77M | – |
| Q4 FY2022 | Dec 31, 2022 | -$35.50M | – |
| Q3 FY2022 | Sep 30, 2022 | -$30.00M | – |
| Q2 FY2022 | Jun 30, 2022 | -$34.60M | – |
| Q1 FY2022 | Mar 31, 2022 | -$29.02M | – |
| Q4 FY2021 | Dec 31, 2021 | -$19.40M | – |
| Q3 FY2021 | Sep 30, 2021 | -$18.80M | – |
| Q2 FY2021 | Jun 30, 2021 | -$19.80M | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.56M | – |
| Q4 FY2020 | Dec 31, 2020 | -$17.11M | – |
| Q3 FY2020 | Sep 30, 2020 | -$15.56M | – |
| Q2 FY2020 | Jun 30, 2020 | -$17.17M | – |
| Q1 FY2020 | Mar 31, 2020 | -$17.61M | – |
| Q4 FY2019 | Dec 31, 2019 | -$16.45M | – |
| Q3 FY2019 | Sep 30, 2019 | -$13.05M | – |
See a number that looks wrong?